Atrial Fibrillation Trial, Recruiting NCT07024927 Sponsor: Beijing Anzhen Hospital Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT07024927
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Atrial Fibrillation (AF) Group

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with atrial fibrillation (an irregular heart rhythm), including types that come and go or that persist over time
  • People who are scheduled to have their first-ever catheter ablation procedure for atrial fibrillation (a procedure that uses energy to correct abnormal heart signals)
  • People whose procedure will use a 3D heart mapping system
  • People who are willing and able to sign a consent form and attend all required follow-up appointments as set out in the study plan

Who may not be able to join:

  • People with serious heart defects present from birth (such as certain complex structural heart conditions)
  • People whose atrial fibrillation is caused by a clearly reversible condition, such as an overactive thyroid, recovery from surgery, or acute alcohol intoxication
  • People who have experienced unstable chest pain or a heart attack within the 30 days before enrolling in the study
  • People with a serious active infection, such as sepsis or septic shock
  • People for whom blood-thinning medication is not medically suitable
  • People who are currently taking part in another interventional clinical trial that could affect this study's results
  • People whom the trial investigator considers unsuitable for any other medical reason

Ventricular Tachycardia (VT) Group

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with ventricular tachycardia (a fast, abnormal heart rhythm originating in the lower chambers of the heart) linked to an underlying heart condition, such as prior heart attack, coronary artery disease, or certain types of heart muscle disease
  • People who are scheduled to have their first-ever catheter ablation procedure for ventricular tachycardia
  • People whose procedure will use a 3D heart mapping system
  • People who are willing and able to sign a consent form and attend all required follow-up appointments as set out in the study plan

Who may not be able to join:

  • People whose ventricular tachycardia is caused by a temporary or reversible condition, such as an acute lack of blood to the heart or a severe imbalance of salts in the blood
  • People with ventricular tachycardia that occurs without any underlying structural heart condition
  • People who have had heart surgery within the 60 days before the planned procedure
  • People with serious blood-clotting disorders (confirm with trial site)
  • People with severely reduced heart pumping function, where the heart is pumping less than 20% of its normal capacity
  • People with a serious active infection, such as sepsis or septic shock
  • People who are currently taking part in another interventional clinical trial that could affect this study's results
  • People whom the trial investigator considers unsuitable for any other medical reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Deyong Long, Beijing Anzhen Hospital

Phone: +86 (010) 84005361

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Beijing Anzhen Hospital
Registry
ClinicalTrials.gov
Start date
21 October 2025
Est. completion
1 June 2032

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Freedom from any documented atrial arrhythmia in 12 months after the index ablation procedure; Composite outcomes of ventricular tachycardia recurrence, cardiovascular hospitalization, or death during the 12-month follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov